PrEP Update

How generic medicines are helping reshape pre-exposure prophylaxis (PrEP)

Presenters include Robert Pilarski, MD; Michael Fanous, PharmD, RPh, and Anne-Marie White, PharmD


Do you or your patients have questions about the available options to prevent and treat HIV?

We invite you to join this live multidisciplinary webinar focused on PrEP as part of an effective strategy to prevent the risk of the sexual transmission of HIV and options to overcome potential cost barriers.

Presenters will talk about clinical research on the efficacy of PrEP and the strong correlation to adherence. Through case examples, they will offer their guidance on identifying appropriate candidates for PrEP treatment and best practices to promote successful outcomes.

This program will also explore the interchangeability of generic and brand name products and how the use of generic antiretrovirals can provide financial benefits to patients and the Canadian healthcare system.

Join your colleagues for a live webinar.

Following this one-hour program, you will have the opportunity to participate in a half-hour interactive Q&A with the presenters.
To help accommodate your schedule, several date and time options are available for the English version of this webinar.

Presented by Drs. Pilarski and Fanous

Presented by Dr. Pilarski and Anne-Marie White

Presented by Drs. Pilarski and Fanous


February 21, 2018

5:00 PM EST


February 22, 2018

9:00 AM EST

Presented by Dr. Pilarski and Anne-Marie White


March 08, 2018

8:00 PM EST


March 09, 2018

12:00 PM EST

Registration is required to complete your accreditation.

Cette présentation est également disponible en français aux dates suivantes

Présenté par : Dr Pilarski et Anne-Marie White


15 février 2018

20h HNE


16 février 2018

12h HNE

Pour de plus amples renseignements sur le programme et les session disponibles, consultez le site Web



Robert Pilarski, MD


Dr. Robert Pilarski graduated from the Sherbrooke University Medical School, and completed his residency in Family Medicine at the same institution. He has been an HIV and AIDS Prevention activist, and has pursued an epidemiological interest in HIV and STI since his family medicine residency. Dr. Pilarski delivers primary health care at the Clinique médicale La Licorne (The Unicorn Medical Clinic) in Montreal, Quebec, a newly founded HIV/STI clinic after having worked for almost a decade in one of the largest HIV clinics in the province of Quebec. Dr. Pilarski also participates in HIV clinical research. He implements HIV treatment as prevention and is one of the pioneers of pre-exposure prophylaxis also known as PreP.

Michael Fanous, PharmD, RPh


Dr. Michael Fanous is an AIDS activist who happens to also be an HIV pharmacist in Toronto, primarily serving the LGBTQ community. He began working in Canada’s largest HIV clinic, Maple Leaf Medical, over 15 years ago when he witnessed the challenges of managing patients’ antiretroviral therapy and the rise of undetectable status as a hallmark of HIV treatment. Dr. Fanous earned his Doctor of Pharmacy degree in 2008 from Union University in New York. Driven by experiences that he, and many of his friends, had in overcoming and accessing gay-friendly and knowledgeable providers, began volunteering as a counsellor in Toronto’s Gay Village. As an activist, Dr. Fanous continues in the fight against HIV/AIDS through improving HIV awareness, research projects, and opposing HIV stigma. As an HIV pharmacist, he advocates for access to care through, the only LGBTQ-owned pharmacy practice in Ontario devoted to helping people navigate the complexities of accessing HIV treatment, PrEP, PEP and Hepatitis C medications.

Anne-Marie White, PharmD


Anne-Marie White works with a large, HIV-infected clientele in a Montreal pharmacy. Her empathy, listening skills and communication abilities have made her an important asset in promoting health to her patients. She is greatly devoted to her pharmacist profession; always seeking solutions to problems and fulfilling her role as an accessible first-line professional.

Learning objectives

Learning Objectives

  1. Describe the efficacy of oral emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) in providing protection against the acquisition of HIV infection
  2. Determine how to identify an at-risk person who would be an appropriate candidate for PrEP
  3. Explore best practices for the consistent and correct use of PrEP as an effective strategy to help prevent the sexual transmission of HIV
  4. Discuss the importance of adherence to maximize PrEP efficacy
  5. Understand the fundamental principles and benefits of bioequivalence testing
  6. Review the cost and comparative bioavailability studies between generic and brand name FTC/TDF

This Group Learning program has been certified by the College of Family Physicians of Canada and the Ontario and Quebec Chapters for up to 1.5 Mainpro+ credits.

The Canadian Council on Continuing Education in Pharmacy has accredited this program for 1.5 CEUs.
Activity number: 1160-2017-2241-L-P | Date accredited: Dec. 8, 2017 | Accreditation expiry date: Dec. 8, 2018

Cette activité de formation continue a été accréditée par l’OPQ qui accordera 1,0 UFC aux pharmaciens qui y auront assisté.
Numéro d’activité : 1820 | Date d’accréditation : 24 janvier 2018 | Date d’expiration de l’accréditation : 24 janvier 2019

This program is supported in part by an educational grant from Teva Canada.

Invite a colleague

Help empower physicians and pharmacists in your professional network to answer common questions about PrEP.

Add another colleague


* Required